Ivan Gur1, Amir Giladi2, Yonathan Nachum Isenberg3, Ami Neuberger4,5, Anat Stern4. 1. Internal Medicine C, Rambam Health Care Campus, Haifa, Israel. 2. Oncode Institute, Hubrecht Institute, Utrecht, The Netherlands. 3. Department of Hematology, Rambam Health Care Campus, Haifa, Israel. 4. Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel. 5. Department of COVID-19-19 "Keter", Rambam Health Care Campus, Haifa, Israel.
Abstract
BACKGROUND: The clinical presentation of coronavirus disease 19 (COVID-19) is the result of intricate interactions between the novel coronavirus and the immune system. In patients with hematologic malignancies (HM), these interactions dramatically change the clinical course and outcomes of COVID-19. SUMMARY: Patients with HM and COVID-19 are at an increased risk for prolonged viral shedding, more protracted and severe presentation, and death, even when compared to other immunocompromised hosts. HM (e.g., multiple myeloma, chronic lymphocytic leukemia) and anticancer treatments (e.g., anti-CD20 agents) that impair humoral immunity markedly increase the risk of severe COVID-19 as well as protracted viral shedding and possibly longer infectivity. Cytokine release syndrome (CRS) is an important player in the pathophysiology of severe and fatal COVID-19. Treatments targeting specific cytokines involved in CRS such as interleukin-6 and Janus kinase have proven beneficial in COVID-19 patients but were not assessed specifically in HM patients. Although neutropenia (as well as neutrophilia) was associated with increased COVID-19 mortality, granulocyte colony-stimulating factors were not beneficial in patients with COVID-19 and may have been associated with worse outcomes. Decreased levels of T lymphocytes and especially decreased CD4+ counts, and depletion of CD8+ lymphocytes, are a hallmark of severe COVID-19, and even more so among patients with HM, underlying the important role of T-helper dysfunction in severe COVID-19. In HM patients with intact cellular immunity, robust T-cell responses may compensate for an impaired humoral immune system. Further prospective studies are needed to evaluate the mechanisms of severe COVID-19 among patients with HM and assess the efficacy of new immunomodulating COVID-19 treatments in this population. KEY MESSAGES: Understanding the immunopathology of COVID-19 has greatly benefited from the previous research in patients with HM. So far, no COVID-19 treatments were properly evaluated in patients with HM. Patients with HM should be included in future RCTs assessing treatments for COVID-19.
BACKGROUND: The clinical presentation of coronavirus disease 19 (COVID-19) is the result of intricate interactions between the novel coronavirus and the immune system. In patients with hematologic malignancies (HM), these interactions dramatically change the clinical course and outcomes of COVID-19. SUMMARY: Patients with HM and COVID-19 are at an increased risk for prolonged viral shedding, more protracted and severe presentation, and death, even when compared to other immunocompromised hosts. HM (e.g., multiple myeloma, chronic lymphocytic leukemia) and anticancer treatments (e.g., anti-CD20 agents) that impair humoral immunity markedly increase the risk of severe COVID-19 as well as protracted viral shedding and possibly longer infectivity. Cytokine release syndrome (CRS) is an important player in the pathophysiology of severe and fatal COVID-19. Treatments targeting specific cytokines involved in CRS such as interleukin-6 and Janus kinase have proven beneficial in COVID-19 patients but were not assessed specifically in HM patients. Although neutropenia (as well as neutrophilia) was associated with increased COVID-19 mortality, granulocyte colony-stimulating factors were not beneficial in patients with COVID-19 and may have been associated with worse outcomes. Decreased levels of T lymphocytes and especially decreased CD4+ counts, and depletion of CD8+ lymphocytes, are a hallmark of severe COVID-19, and even more so among patients with HM, underlying the important role of T-helper dysfunction in severe COVID-19. In HM patients with intact cellular immunity, robust T-cell responses may compensate for an impaired humoral immune system. Further prospective studies are needed to evaluate the mechanisms of severe COVID-19 among patients with HM and assess the efficacy of new immunomodulating COVID-19 treatments in this population. KEY MESSAGES: Understanding the immunopathology of COVID-19 has greatly benefited from the previous research in patients with HM. So far, no COVID-19 treatments were properly evaluated in patients with HM. Patients with HM should be included in future RCTs assessing treatments for COVID-19.
Authors: Tatjana Bilich; Malte Roerden; Yacine Maringer; Annika Nelde; Jonas S Heitmann; Marissa L Dubbelaar; Andreas Peter; Sebastian Hörber; Jens Bauer; Jonas Rieth; Marcel Wacker; Fiamma Berner; Lukas Flatz; Stefanie Held; Peter Brossart; Melanie Märklin; Philipp Wagner; Eva Erne; Reinhild Klein; Hans-Georg Rammensee; Helmut R Salih; Juliane S Walz Journal: Cancer Discov Date: 2021-05-19 Impact factor: 39.397
Authors: Anthony C Gordon; Paul R Mouncey; Farah Al-Beidh; Kathryn M Rowan; Alistair D Nichol; Yaseen M Arabi; Djillali Annane; Abi Beane; Wilma van Bentum-Puijk; Lindsay R Berry; Zahra Bhimani; Marc J M Bonten; Charlotte A Bradbury; Frank M Brunkhorst; Adrian Buzgau; Allen C Cheng; Michelle A Detry; Eamon J Duffy; Lise J Estcourt; Mark Fitzgerald; Herman Goossens; Rashan Haniffa; Alisa M Higgins; Thomas E Hills; Christopher M Horvat; Francois Lamontagne; Patrick R Lawler; Helen L Leavis; Kelsey M Linstrum; Edward Litton; Elizabeth Lorenzi; John C Marshall; Florian B Mayr; Daniel F McAuley; Anna McGlothlin; Shay P McGuinness; Bryan J McVerry; Stephanie K Montgomery; Susan C Morpeth; Srinivas Murthy; Katrina Orr; Rachael L Parke; Jane C Parker; Asad E Patanwala; Ville Pettilä; Emma Rademaker; Marlene S Santos; Christina T Saunders; Christopher W Seymour; Manu Shankar-Hari; Wendy I Sligl; Alexis F Turgeon; Anne M Turner; Frank L van de Veerdonk; Ryan Zarychanski; Cameron Green; Roger J Lewis; Derek C Angus; Colin J McArthur; Scott Berry; Steve A Webb; Lennie P G Derde Journal: N Engl J Med Date: 2021-02-25 Impact factor: 91.245
Authors: Tiziano Barbui; Alessandro Maria Vannucchi; Alberto Alvarez-Larran; Alessandra Iurlo; Arianna Masciulli; Alessandra Carobbio; Arianna Ghirardi; Alberto Ferrari; Giuseppe Rossi; Elena Elli; Marcio Miguel Andrade-Campos; Mercedes Gasior Kabat; Jean-Jaques Kiladjian; Francesca Palandri; Giulia Benevolo; Valentin Garcia-Gutierrez; Maria Laura Fox; Maria Angeles Foncillas; Carmen Montoya Morcillo; Elisa Rumi; Santiago Osorio; Petros Papadopoulos; Massimiliano Bonifacio; Keina Susana Quiroz Cervantes; Miguel Sagues Serrano; Gonzalo Carreno-Tarragona; Marta Anna Sobas; Francesca Lunghi; Andrea Patriarca; Begona Navas Elorza; Anna Angona; Elena Magro Mazo; Steffen Koschmieder; Marco Ruggeri; Beatriz Cuevas; Juan Carlos Hernandez-Boluda; Emma Lopez Abadia; Blanca Xicoy Cirici; Paola Guglielmelli; Marta Garrote; Daniele Cattaneo; Rosa Daffini; Fabrizio Cavalca; Beatriz Bellosillo; Lina Benajiba; Natalia Curto-Garcia; Marta Bellini; Silvia Betti; Valerio De Stefano; Claire Harrison; Alessandro Rambaldi Journal: Leukemia Date: 2021-01-07 Impact factor: 11.528
Authors: Erik Gaitzsch; Verena Passerini; Elham Khatamzas; Carolin D Strobl; Maximilian Muenchhoff; Clemens Scherer; Andreas Osterman; Michael Heide; Anna Reischer; Marion Subklewe; Alexandra Leutbecher; Benjamin Tast; Adrian Ruhle; Tobias Weiglein; Stephanie-Susanne Stecher; Hans J Stemmler; Martin Dreyling; Philipp Girl; Enrico Georgi; Roman Wölfel; Laura Mateyka; Elvira D'Ippolito; Kilian Schober; Dirk H Busch; Juliane Kager; Christoph D Spinner; Matthias Treiber; Sebastian Rasch; Tobias Lahmer; Roman Iakoubov; Jochen Schneider; Ulrike Protzer; Christof Winter; Jürgen Ruland; Michael Quante; Oliver T Keppler; Michael von Bergwelt-Baildon; Johannes Hellmuth; Oliver Weigert Journal: Hemasphere Date: 2021-06-28
Authors: Katie Maurer; Anna Saucier; Haesook T Kim; Utkarsh Acharya; Clifton C Mo; Julie Porter; Cindy Albert; Corey Cutler; Joseph H Antin; John Koreth; Mahasweta Gooptu; Rizwan Romee; Catherine J Wu; Robert J Soiffer; Sarah Nikiforow; Caron Jacobson; Vincent T Ho Journal: Blood Adv Date: 2021-02-09